Relative to Rare Disease Day.
ACR 33 is a nonbinding legislative resolution that designates February 28, 2025, as Rare Disease Day in California. The resolution expresses the Legislature’s recognition of the challenges faced by people living with rare diseases and disorders, including difficulty obtaining accurate diagnoses, finding specialists, and accessing effective treatments. It also highlights the scale of rare disease in the United States, the impact on children and families, and the role of federal and state efforts in advancing research and treatment.
The measure places California’s support behind broader efforts to improve awareness, early diagnosis, diagnostics, cures, and treatment development for rare diseases. In doing so, it references the federal Orphan Drug Act, FDA rare disease initiatives, NIH research, and California’s own Rare Disease Advisory Council and life sciences sector. The resolution does not create a regulatory program or mandate new services; instead, it serves as an official statement of legislative support and recognition.
ACR 33 does not amend the California Codes or impose new legal duties. Its practical effect is symbolic and commemorative: it formally designates a date and signals legislative support for rare disease patients, researchers, clinicians, and advocacy efforts. The resolution may help elevate awareness and reinforce existing state and federal efforts related to rare disease research, diagnosis, and treatment access, but it does not directly change eligibility rules, coverage requirements, or agency authority.
The sentiment around the bill appears strongly supportive and largely unanimous. The resolution passed the Assembly 10-0 and the Senate 36-0, indicating broad bipartisan agreement. The bill’s language is also affirming and advocacy-oriented, emphasizing hope, awareness, and the need for continued research and treatment development for rare disease communities.
There is little visible contention in the available record. Because the measure is a ceremonial resolution, it does not appear to have generated debate over costs, mandates, or regulatory changes. The main emphasis in the text is on recognition and awareness, with support for patients and families; any underlying policy concerns are indirect, such as the ongoing need for access to diagnosis, specialists, and affordable treatment, but no opposing viewpoints are reflected in the votes or transcripts provided.